Hosp. Univ. Hm Sanchinarro

Madrid 28050

6 studies enrolling now · 17 studies all time

What they study most

Advanced or Metastatic Colorectal Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Castration-Resistant Prostatic Neoplasms, Colorectal Neoplasms, Gastrointestinal Neoplasms, Metastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer, Multiple Myeloma, Neoplasms, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

Studies at this site

• JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC — Recruiting now
• A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma — Recruiting now
• A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers — Recruiting now
• A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors — Recruiting now
• A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer — Recruiting now
• A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer — Recruiting now
• A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors — Recruiting now
• A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy — Running, not enrolling
• A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder — Running, not enrolling
• A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure — Running, not enrolling
• A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer — Running, not enrolling
• A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer — Running, not enrolling
• A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer — Running, not enrolling
• A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer — Running, not enrolling
• A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment — Running, not enrolling
• A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer — Running, not enrolling
• A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer — Completed